

Sanofi launches new medicine, bringing hope to cardiovascular disease patients

Sanofi has launched its latest medicine Praluent (alirocumab) which reduces low-density lipoprotein cholesterol levels (LDL-C). The drug protects patients against the risks of major adverse cardiovascular events (MACE).